Pinning down the polo-box domain.
Polo-like kinase 1 (Plk1) appears to be an attractive target for anticancer therapy. In this issue of Chemistry & Biology, Reindl et al. (2008) describe the identification of a small molecule called Poloxin that appears to interfere with the function of the polo-box domain (PBD) of Plk1.
Lee
Kyung S
KS
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA. kyunglee@mail.nih.gov
Idle
Jeffrey R
JR
D020134:Catalytic Domain; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism; D015195:Drug Design; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism; D000097869:Polo-Like Kinase 1
D018797:Cell Cycle Proteins; D047428:Protein Kinase Inhibitors; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000097869:Polo-Like Kinase 1